biosimilar portfolio

SK Nexilis Co., the world’s largest copper foil maker, is in the final stage of negotiations to sell its thin film manufacturing division to A...

Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, is expected to post its best-ever annual revenue this year after sal...

HO CHI MINH CITY – South Korean apparel maker Hansae Yes24 Group has set its sights on the auto parts business as a new growth driver to diver...

Sono Hospitality Group, South Korea’s largest resort operator, will add low-cost carrier Air Premia Inc. to its bulging portfolio after agreei...

LG Energy Solution Ltd. has vowed to more than double its sales in five years to 67 trillion won ($50 billion) by diversifying its battery products ...

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...

South Korea's Kolon FnC said on Thursday that it will launch the Italian high-end fashion brand N21 in South Korea.In August, Kolon FnC has secured ...

South Korean exchange-traded funds (ETFs) tracking KEDI, an index set created by The Korea Economic Daily, are booming on growing investor demand fo...

Cosmax NBT, Inc., a health supplement original development manufacturing (ODM) affiliate of South Korea's Cosmax Group, announced on Monday that it ...

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korea's Samsung Asset Management announced on Thursday that it newly published the KODEX Brokerage ISA Investment Guidebook for individual inv...

South Korea’s No. 2 petrochemicals manufacturer Lotte Chemical Corp. is set to more than halve its basic chemicals business by 2030 in its por...

Hyundai Glovis Co., the logistics unit of South Korea’s Hyundai Motor Group, is entering the liquefied natural gas transportation business wit...

STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Korea Investment & Securities Co. will scale up its collateralized loan obligation (CLO) business with New York-based investment firm Anchorage ...

Sovereign wealth fund Korea Investment Corporation (KIC) seeks opportunities in direct lending for companies that are not cyclically sensitive and g...

SK Inc., the holding company of South Korea’s second-largest business group SK, is in talks with Joyvio Group to sell its entire 13.3% stake i...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

SK Innovation Co., South Korea’s top energy company, is slated to adjust its business portfolios for long-term growth while not planning to sl...

South Korea’s mergers and acquisitions market is poised to bounce back after a bleak first quarter, with 22.3 trillion won ($16 billion) worth...

South Korea’s current account surplus touched a near three-year high in February as goods exports continued to grow on strong overseas sales o...

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

South Korea's Hanwha Solutions Corp. is accelerating its entry into the global market with proprietary technology in high-voltage cable materials.Ha...

South Korea's KT Corp. announced on Wednesday that it signed a memorandum of understanding (MOU) with the domestic company Novatek which specializes...

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...

South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...